Comparison · NCT01229943-sae
Arm I (Octreotide Acetate and Everolimus) vs Arm II (Octreotide Acetate, Everolimus, and Bevacizumab): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I (Octreotide Acetate and Everolimus) vs Arm II (Octreotide Acetate, Everolimus, and Bevacizumab): serious adverse events. Trial comparisons, record NCT01229943-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01229943-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.27 | 0.182 | 0.381 | wilson | |
| Risk in group 2 | 0.425 | 0.318 | 0.539 | wilson | |
| Risk difference, group 1 minus group 2 | -0.154 | -0.299 | -0.000598 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.636 | 0.402 | 1.01 | log | |
| Odds ratio, group 1 over group 2 | 0.502 | 0.251 | 1 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Arm I (Octreotide Acetate and Everolimus) than on Arm II (Octreotide Acetate, Everolimus, and Bevacizumab) | 6.48 | 3.35 | 1,670 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I (Octreotide Acetate and Everolimus) | Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28 and octreotide acetate 20 mg IM on day 1.~Everolimus: Given PO~Octreotide Acetate: Given IM | 20 | 74 | EG000 |
| Group 2 | Arm II (Octreotide Acetate, Everolimus, and Bevacizumab) | Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28, octreotide acetate 20 mg IM on day 1 and bevacizumab 10 mg/kg IV on days 1 and 15.~Bevacizumab: Given IV~Everolimus: Given PO~Octreotide Acetate: Given IM | 31 | 73 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
- NCT number
- NCT01229943
- Phases
- PHASE2
- Conditions
Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Pancreatic Vipoma
- Interventions
- Bevacizumab, Everolimus, Octreotide Acetate
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2016-02-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01229943?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01229943-sae